Abstract

SGLT-2 INHIBITOR TREATMENT AND INFLUENCE ON ALBUMINURIA IN TYPE 2 DIABETES

Nikolay Krasimirov Kostadinov* and Tzvetelina Tzvetanova Totomirova

Abstract

Late complications of diabetes mellitus represent a serious problem for patients. Diabetes mellitus is the most common cause of the development of chronic kidney disease (CKD). Early identification and management of CKD is of utmost importance to minimize the risk of severe cardiovascular events and premature loss of life. There are advances in available glucose-lowering agents for the treatment of type 2 diabetes that not only modify the disease itself, but also provide important benefits such as nephroprotection and cardioprotection. Sodium glucose cotransporter 2 (SGLT2) inhibitors have demonstrated significant benefits in reducing major adverse cardiovascular events, heart failure hospitalization, mortality, plus the renoprotective benefit they provide.

Keywords: diabetes type 2, SGLT 2 inhibitors, renal function microalbuminuria.